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Abstract 
Proprotein  convertase  subtilisin/kexin  type  9  (PCSK9)  is  a  promising  therapeutic  target  for 
treating coronary heart disease. We report a novel antibody 1B20 that binds to PCSK9 with 
sub-nanomolar affinity and antagonizes PCSK9 function in-vitro. In CETP/LDLR-hemi mice two 
successive doses of 1B20, administered 14 days apart at 3 or 10 mpk, induced dose dependent 
reductions in LDL-cholesterol (≥ 25% for 7-14 days) that correlated well with the extent of PCSK9 
occupancy by the antibody. In addition, 1B20 induces increases in total plasma antibody-bound 
PCSK9 levels and decreases in liver mRNA levels of SREBP-regulated genes PCSK9 and LDLR, with 
a time course that parallels decreases in plasma LDL-cholesterol (LDL-C). Consistent with this 
observation in mice, in statin-responsive human primary hepatocytes, 1B20 lowers PCSK9 and 
LDLR mRNA levels and raises serum steady-state levels of antibody-bound PCSK9. In addition, 
mRNA levels of several SREBP regulated genes involved in cholesterol and fatty-acid synthesis 
including ACSS2, FDPS, IDI1, MVD, HMGCR, and CYP51A1 were decreased significantly with 
antibody treatment of primary human hepatocytes. In rhesus monkeys, subcutaneous (SC) dosing 
of 1B20 dose-dependently induces robust LDL-C lowering (maximal ~70%), which is correlated 
with  increases  in  target  engagement  and  total  antibody-bound  PCSK9  levels.  Importantly,  a 
combination of 1B20 and Simvastatin in dyslipidemic rhesus monkeys reduced LDL-C more than 
either agent alone, consistent with a mechanism of action that predicts additive effects of an-
ti-PCSK9 agents with statins. Our results suggest that antibodies targeting PCSK9 could provide 
patients powerful LDL lowering efficacy on top of statins, and lower cardiovascular risk. 
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Introduction 
Cardiovascular  disease  is  a  significant  public 
health burden in the US and other developed coun-
tries. Although statin therapy has been used success-
fully  in  treating  dyslipidemia  and  reducing  cardio-
vascular events  in  humans, a significant  number of 
patients still do not reach their target LDL-C levels, as 
set  out  by  the  Coordinating  Committee  of  the  Na-
tional  Cholesterol  Education  Program(1,  2).  Addi-
tionally, of those treated that do reach their LDL-C 
goal, many continue to have cardiovascular events(3). 
There is also a segment of the patient population that 
are statin intolerant(4). Therefore, there is a significant 
unmet medical need to lower LDL-C and cardiovas-
cular risk in these high risk patients. 
Proprotein  convertase  subtilisin/kexin  type  9 
(PCSK9), which interacts with and promotes cellular 
degradation of the low density lipoprotein receptor 
(LDLR), is a promising therapeutic target for treating 
hypercholesterolemia  and  coronary  heart  disease 
(5-13). A strong link between PCSK9, LDL cholesterol 
and  coronary  heart  disease  has  been  established  in 
humans.  Several  large  human  genetic  studies  have 
shown that putative gain- or loss-of function mutants 
(missense or truncation mutations) correlate with in-
creased or reduced plasma LDL levels and CHD, re-
spectively (14-18). A recent genome-wide association 
study further bolstered the importance of PCSK9 by 
establishing a link between a single nucleotide poly-
morphism  at  a  locus  near  PCSK9  with  early  onset 
myocardial  infarction  (19).  A  clear  link  between 
PCSK9 and LDL-C is also observed in animal studies. 
PCSK9 knockout mice have decreased plasma LDL-C 
(20). In non-human primates, PCSK9 knockdown by 
siRNA or inhibition by a monoclonal antibody also 
leads to decreased plasma LDL (21-23). 
There is extensive evidence that plasma PCSK9 
raises LDL cholesterol levels by binding to cell surface 
LDLR  and  targeting  the  receptor  to  lysosome  for 
degradation(9-13,  24-35).  Statins  exert  their  plasma 
LDL lowering effect by inhibiting hepatic cholesterol 
biosynthesis,  raising  SREBP  (Sterol  Regulatory  Ele-
ment  binding  Protein)  tone  in  hepatocytes,  and 
therefore increasing LDLR transcription and protein 
level  (36-40).  However,  PCSK9,  another  SREBP  re-
sponsive  gene,  is  also  induced  and  could  attenuate 
statin's LDLR raising effect (20, 41-44). Therefore, in-
troducing  a  PCSK9  antagonist  on  top  of  a  statin  is 
predicted to be additive to statins and further lower 
LDL-C.  Here  we  describe  the  characterization  of  a 
monoclonal  antibody  1B20,  which  binds  to  PCSK9 
with high affinity, disrupts the PCSK9-LDLR interac-
tion, and inhibits the effect of PCSK9 on cellular LDL 
uptake. Treatment with the 1B20 anti-PCSK9 mono-
clonal antibody via either IV or SC dosing in mice and 
rhesus  monkeys  led  to  robust  LDL-C  lowering  in 
plasma,  decreased  liver  PCSK9  and  LDLR  mRNAs, 
and  transient  increases  in  total  plasma  levels  of 
PCSK9. 1B20 and simvastatin showed additive effects 
in LDL-C lowering in dyslipidemic monkeys with a 
genetic  predisposition to  metabolic syndrome. Con-
sistent  with  in-vivo  data  in  mice  and  monkeys,  in 
human primary hepatocytes 1B20 treatment reduces 
PCSK9 and LDLR mRNAs on top of simvastatin, in-
hibits cellular PCSK9 uptake, and leads to increases in 
secreted PCSK9 protein.  
Results 
PCSK9 affinity characterization 
1B20 binding kinetics was measured using sur-
face plasmon resonance in a Biacore 2000. Polyclonal 
anti-human IgG antibody was covalently coupled to 
the surface and 1B20 was captured. Association and 
dissociation rates of soluble PCSK9 protein were then 
determined and used to calculate the affinity constant 
KD  =  kd/ka.  Repeated  determinations  were  made 
against  recombinant  soluble  human,  mouse,  rhesus 
and rat PCSK9-V5-His proteins. The determined ki-
netic and equilibrium constants are given in Table 1. 
1B20 binds to human, rat, rhesus, and mouse PCSK9 
with high affinity at KD of 0.3, 4.5, 0.65, and 1 nM re-
spectively. 
Table 1. Affinity characterization of 1B20 by surface 
plasmon resonance (Biacore 2000). Values are expressed as 
arithmetic means ± standard errors. 
   Human 
PCSK9 
Rat PCSK9  Rhesus 
PCSK9 
Mouse 
PCSK9 
ka (1/Ms)  1.4E05 ± 
1.3E04 
1.5E05 ± 
3.6E03 
1.6E05 ± 
4.7E03 
1.5E05 ± 
1.6E04 
kd (1/s)   4.0E-05 ± 
5.8E-07 
7.5E-04 ± 
1.4E-05 
1.0E-04 ± 
5.9E-06 
1.5E-04 ± 
7.1E-06 
KD (M)  3.0E-10 ± 
3.0E-11 
4.5E-09 ± 
1.3E-10 
6.5E-10 ± 
2.4E-11 
1.0E-9 ± 
6.4E-11 
Kinetic constants for association rate (ka) and for dissociation rate 
(kd) were determined and used to calculate the apparent equilib-
rium affinity constant (KD), using the equation KD = kd/ka. The 
values represent the averages of three experiments. 
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In vitro functional efficacy of 1B20 for PCSK9 
The  biological  activity  of  1B20  was  examined 
using  in vitro  assays  that  measure  PCSK9  function. 
First,  1B20  was  tested  in  a  cell-based  assay  that 
measures  PCSK9-dependent  effects  on  cellular 
LDL-uptake,  where  LDL  is  fluorescently  labeled 
(AF-LDL). Recombinant PCSK9 protein (1 μg/ml, 13 
nM)  was  added  exogenously  to  HepG2  cells  in  the 
presence or absence of increasing amounts of the an-
ti-PCSK9 mAb 1B20. This antibody dose-dependently 
and completely inhibited the effects of PCSK9 on cel-
lular AF-LDL-uptake. The addition of 1B20 to cells in 
the absence of exogenously added PCSK9 had no ef-
fect on cellular AF-LDL uptake (data not shown), in-
dicating that the effects of 1B20 are specific to inhibi-
tion of exogenously added PCSK9 protein. In HepG2 
cells the regulation of cell surface LDLR presumably 
is not by secreted PCSK9. One possible explanation is 
that the level of secreted PCSK9 in HepG2 cells is ex-
tremely low (~ 0.03 nM) compared to human plasma 
PCSK9 level (~5 nM), therefore the minimal level of 
secreted PCSK9 in this cell line does not have much 
impact  on  cell  surface  LDLR  protein.  When  exoge-
nous  PCSK9  was  added  to  these  cells,  LDL  uptake 
was significantly decreased, and the addition of 1B20 
antibody  reversed  this  decrease.  We  have  not  fully 
explored  factors  that  regulate  LDLR,  but  published 
information from Dong et al (reference#46) has shown 
that  Idol  is  involved  in  the  regulation  of  LDLR  in 
HepG2  cells.  Because  HepG2  is  a  cancer  cell  line 
which does not resemble liver cells very well at cel-
lular  or  molecular  levels,  we  switched  to  primary 
human hepatocytes in later studies. 
While the results indicate that the potencies of 
1B20 for all species of PCSK9 are equivalent (Table 2), 
the lowest theoretical IC50 that is measurable in this 
assay  is  ~  4  nM.  This  assay  will  not  differentiate 
modest potency differences lower than 4 nM as would 
be predicted by the binding affinity data (Table 1). 
The  ability  of  1B20  to  directly  inhibit  the 
PCSK9-LDLR  interaction,  a  critical  protein-protein 
interaction  that  is  required  for  PCSK9's  effects  on 
cellular LDL-uptake, was analyzed by the method of 
Surface  plasmon  resonance  (SPR)  on  a  Biacore  in-
strument.  In  this  assay,  recombinant  human  LDLR 
protein was immobilized on a CM5 sensor chip using 
standard coupling chemistry. Either human, mouse, 
rhesus or rat PCSK9 were diluted in running buffer to 
a  concentration  of  around  25  nM  and  varying 
amounts of 1B20 were added. As shown in Table 2, 
1B20 is a potent antagonist of the interaction of hu-
man,  mouse,  rhesus,  rat  PCSK9  toward  LDLR.  The 
IC50 range is from 6 to 11 nM. The IC50 is less than the 
PCSK9 concentration and close to the floor of the as-
say sensitivity (~ 6  nM), consistent  with the notion 
that the true inhibition constant is most likely much 
lower than the IC50 value.  
 
 
Table 2. 1B20 is a full antagonist of PCSK9 – LDLR in-
teraction in vitro, and blocks PCSK9 inhibitory effect on 
cellular LDL uptake in HepG2 cells. 
 Protein  IC50 (nM) on PCSK9 – 
LDLR interactionA 
IC50 (nM) on PCSK9 
inhibitory effect on 
cellular LDL uptakeB 
Human PCSK9   11.4 ± 1.5   4 ± 1  
Mouse PCSK9   5.8 ± 1.4   3 ± 0  
Rhesus PCSK9   11.4 ± 1.4   4 ± 2  
Rat PCSK9   7.8 ± 1.3   3 ± 1  
 
APCSK9 – LDLR interaction was quantified on Biacore instrument. 
Human recombinant LDLR was immobilized on a CM5 sensor chip. 
PCSK9 alone, or PCSK9 with various concentrations of 1B20 was 
added, and resonance units were measured. Data are expressed as 
means ± standard deviation of at least three experiments. BPCSK9 
alone or PCSK9 pre-incubated with 1B20, together with 
AF-546-LDL, was added to cultured HepG2 cells. Cellular uptake of 
AF546-LDL was measured. Values are expressed as arithmetic 
means ± standard deviations of at least three experiments. 
 
 
LDL-lowering efficacy of 1B20 in mice (multi-
ple-dosing) 
Typically, wild-type mice are not ideal models 
because their baseline circulating levels of LDL-C are 
low (~ 10 mg/dl) and the circuitry of their lipid me-
tabolism is such that they are generally unresponsive 
to HMG-CoA reductase inhibitors (Statins). Therefore, 
a  transgenic  mouse  model  expressing  the  human 
CETP  transgene  and  a  single  allele  copy  of  the 
LDL-receptor  (CETPtg[LDLR+/-])  was  utilized  (23). 
By introducing the CETP transgene, mice are able to, 
like humans, undergo reverse cholesterol metabolism 
thereby  decreasing  their  steady-state  HDL-C  levels. 
The single copy of the LDLR further promotes an in-
crease  in  circulating  LDL-C  in  these  mice  and  the 
overall lipid distribution closely mimics that of young 
healthy humans. Additionally, the CETPtg[LDLR+/-] 
mice have circulating levels of PCSK9 that are similar 
to humans (~ 5 nM). A single 1.1 mpk IV dose of 1B20 
(in PBS buffer) induced ~29% LDL-C lowering 48 hr 
post dose. At this time point, the level of serum 1B20 
was  measured  as  3.5  ug/ml  (23  nM).  Similar  LDL 
lowering effects were obtained with IP dosing of this 
antibody (data not shown). The PBS-only control and 
an irrelevant antibody targeting a separate and dis-
tinct antigen had no LDL lowering effects (data not 
shown). Consistent with the proposed mechanism of Int. J. Biol. Sci. 2012, 8 
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LDL-lowering,  1B20  markedly  increased  the  steady 
state levels of hepatic LDL-receptor protein compared 
to the PBS control, as shown in the Western blot in 
Figure  1.  Other  circulating  lipid  levels  including 
high-density  lipoproteins  (HDL)  and  triglycerides 
(TGs) were not affected by 1B20 treatment (data not 
shown).  
 
 
Figure 1. 1B20 lowered LDL-C (A, B) and increased hepatic LDL-receptor protein (C) in a transgenic 
mouse model [CETPtg(LDLR+/-)]. Mice were sacrificed 48 hours after single IV injection of 1B20. Plasma samples 
were collected for LDL-C and HDL-C analysis (A) and liver samples were collected for western blot (C). Note: Comparing 
to wild type C57BL/6 mice, the LDL-C level in these CETPtg(LDLR+/-) mice is relatively high (~66 mg/dL) and the HDL-C 
level is relatively low (~58 mg/dL) (23). Int. J. Biol. Sci. 2012, 8 
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Figure  2.  Effects  of  multiple  doses  given  14  days  apart,  of  either  3  mpk  or  10  mpk  IV  of  1B20  in 
CETPtg(LDLR+/-) mice on 1B20 levels (A), %LDL-C changes (B), % TE (C) and total PCSK9 levels (D). The 
PK profiles were comparable following the first and second doses, suggesting 1B20 does not elicit a strong immune response 
under this dosing regimen (A).1B20 induced a robust 50-70% LDL-C lowering, and the extent of LDL-C lowering was not 
significantly different with the second dose (B). The changes in TE were consistent with the time course of changes in plasma 
LDL-C (B,C). Both doses transiently increased total PCSK9, but no accumulation of this increase was observed with multiple 
dosing (D). 
 
 
To examine the multiple dose effect of 1B20, a 
multidose study in CETPtg(LDLR+/-) mice was per-
formed using either 3 or 10 mg/kg (mpk) doses of 
1B20,  administered  14  days  apart  (Figure  2).  The 
pharmacokinetics (PK) profiles of 1B20 are compara-
ble following the first and the second doses, suggest-
ing  that  1B20  does  not  elicit  a  strong  immune  re-
sponse under this dosing regime (Figure 2A). Addi-
tionally,  a  robust  50-70%  LDL-C  lowering  was  in-
duced by 1B20 and the extent of LDL-C lowering was 
not significantly different with the second dose (Fig-
ure 2B). The 1B20 dose response between 3 mpk and 
10 mpk on LDL lowering was seen only at longer time 
points (day 7 and later, not before day 3). This is likely 
due to the circulating 1B20 levels dropping to limiting 
concentrations  at  longer  time  points  (~1ug/ml  or  7 
nM at day 7 for the 3 mpk dose) compared to circu-
lating PCSK9 levels (~5 nM) in these mice. To access Int. J. Biol. Sci. 2012, 8 
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the occupancy of PCSK9 by 1B20 antibody, two Delfia 
ELISA  assays  were  performed.  One  Delfia  assay 
measures  plasma  total  PCSK9  and  the  other  assay 
measures  free  (unbound)  PCSK9.  The  1B20-bound 
PCSK9  is  calculated  as  the  difference  between  total 
and  free  PCSK9.  The  percent  target  engagement  is 
defined  as  the  percentage  of  1B20-bound  PCSK9  in 
total  PCSK9.  Importantly,  the  changes  in  %  target 
engagement (TE) were consistent with the time-course 
of changes in plasma levels of LDL-C. The duration of 
≥ 25% LDL lowering was 7 days post a 3 mpk dose 
and ~ 14 days post a 10 mpk dose. Both doses of 1B20 
transiently increased total PCSK9 levels significantly; 
4.5 fold for the 3 mpk dose and 7.5 fold for the 10 mpk 
dose with levels returning to baseline at days 14 and 
day 35.  
As part of the multidose study, liver tissues were 
harvested for analysis of gene expression changes. It 
was anticipated that inhibition of PCSK9 would result 
in  an  increase  in  intracellular  liver  cholesterol  con-
centrations;  this  in  turn  would  inactivate  the  tran-
scriptional protein SREBP-2 and result in a suppres-
sion  of  gene  expression  of  PCSK9  and  LDLR.  Con-
sistent with expectations, 1B20 promoted a reduction 
of PCSK9 and LDLR mRNAs that paralleled the time 
course of plasma LDL-reductions (Figure 3). Despite 
this reduction in PCSK9 mRNA levels, the total cir-
culating levels  of PCSK9 increased with 1B20 treat-
ment. This increase in PCSK9 protein most likely is 
due to the sequestering of PCSK9 by 1B20 in the cir-
culation,  which  may  lead  to  slower  degradation  of 
PCSK9  and  higher  steady-state  levels,  rather  than 
increased synthesis. 
In-vivo efficacy in healthy rhesus monkeys (IV & 
SC dose) 
 Sub-cutaneous  (SC)  administration  is  the  pre-
ferred route of delivery in humans. To test the feasi-
bility and aid SC dose selection in humans, a study 
was conducted in healthy rhesus monkeys to evaluate 
PK, PD (pharmacodynamics) and TE (target engage-
ment) of 1B20 following a single SC or IV dose of 1 
and 10 mpk of 1B20. As shown in Figure 4, at 1 mpk, 
SC and IV dosing led to similar serum 1B20 levels. At 
10 mpk, SC dosing of 1B20 led to higher day 2-7 cir-
culating levels of 1B20, possibly due to the extended 
release of 1B20 into circulation after SC dosing. Con-
sistent with the PK profile, at 1 mpk, SC and IV dosing 
led to similar time courses of % LDL changes, while at 
10 mpk, SC dosing led to longer duration of LDL re-
duction with LDL returning to baseline around day 
28, demonstrating a strong PK-PD relationship (Fig-
ure 5). At 1 mpk SC and IV dosing, % TE returned to 
baseline around day 15, which is consistent with the 
time course  of LDL changes; at 10 mpk SC and IV 
dosing, %TE returned to baseline around day 28, and 
is also consistent with the LDL changes, suggesting a 
good TE-PD correlation. Overall, these data demon-
strate a PK-PD-TE correlation. Additionally, similar to 
what was  seen in the  mouse study, 1B20 treatment 
promoted a transient increase in total PCSK9 levels 
(2-3 fold), which returned to baseline levels during the 
study (Figure 6). In summary, both IV and SC dosing 
of 1B20 induced robust LDL-C lowering in healthy, 
normocholesterolemic  monkeys,  and  the  preferred 
route of administration is SC, which makes it amena-
ble for self-injections in humans. 
 
 
Figure 3.  1B20 treatment led to reductions of liver PCSK9 and LDLR mRNAs in mice that paralleled the 
time course of LDL-C reductions in the multiple dosing study. First dose was given at day 0, second dose was given 
at day 14. 1B20 dose response of mRNA decreases correlated with dose response of LDL lowering. Int. J. Biol. Sci. 2012, 8 
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Figure 4.  Comparison of serum 1B20 levels as a function of IV or SC administration of 1 and 10 mpk doses 
of 1B20 in healthy rhesus monkeys. Serum 1B20 levels were higher after 10 mpk dosing than 1 mpk dosing. At 1 mpk, 
SC and IV dosing led to similar serum 1B20 levels. Comparing to IV dosing, SC dosing of 1B20 (10 mpk) led to higher day 2-7 
circulating levels of 1B20, possibly due to the extended release of 1B20 into circulation after SC dosing. The PK profiles are 
consistent with the time courses of LDL lowering (see below). 
 
 
 
Figure 5.  Comparison of %TE and LDL-C changes as a function of IV or SC administration of 1 and 10 mpk 
doses of 1B20 in healthy rhesus monkeys. TE levels after 10 mpk dosing (IV or SC) were higher than TE after 1 mpk. 
SC or IV dosing of 1 mpk 1B20 had similar effects on TE and LDL. SC dosing of 10 mpk 1B20 led to higher %TE and longer 
duration of LDL-C lowering than 10 mpk IV dosing. 
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Figure 6. Effects of a single SC or IV dose of 1 and 10 mpk 1B20 in healthy rhesus monkeys on total and free 
(unbound) levels of plasma PCSK9. In all cases, 1B20 promoted a transient decrease in free PCSK9 and increase in total 
PCSK9 levels (2-3 fold), which returned to baseline at ~2 weeks post treatment. 
 
 
Statin additivity study in metabolic syndrome 
monkeys 
To assess the statin additivity effects of 1B20, a 
study  was  designed  in  a  cohort  of  metabolic  syn-
drome  monkeys.  These  monkeys  naturally  develop 
metabolic  syndrome,  are  overweight  and 
dyslipidemic and have been reported to respond to 
statins (45). Detailed characterization of the metabolic 
syndrome  monkeys  can  be  found  in  reference#45. 
Briefly, the metabolic syndrome (MS) monkeys have 
significantly higher level of plasma insulin (906 pM 
MS vs. 241 pM healthy), HbA1c (6.1% MS vs. 4.3% 
healthy), and lower insulin-stimulated glucose uptake 
rate  (5.3  vs.  12.9  mg/kg  fat-free  mass/min,  MS  vs. 
healthy). 
A multiple arm study was designed to compare 
the effects of simvastatin, 1B20, and simvastatin plus 
1B20 in the same cohort of 10 monkeys. Simvastatin 
was given at a 30 mg/kg/day dose in food treats and 
1B20 was administered IV as a 3 mpk dose. The study 
design is as follows: Monkeys were treated with ve-
hicle in weeks 1 and 2, simvastatin in weeks 3 and 4 
(30mg/kg/day in food), followed by vehicle in weeks 
5 and 6. At the start of week 7, a single 3 mpk IV dose 
of 1B20 was administered to each monkey. Given the 
result  obtained  in  lean  monkeys,  it  was  anticipated 
that LDL-C would return to baseline levels at 14 days 
post this first dose. At the start of week 9, a second 
dose of single 3 mpk IV 1B20 was administered to-
gether  with  daily  dosings  of  simvastatin  in  food 
treats. During the study, weekly plasma samples were 
collected for measurements of LDL-C., total and free 
PCSK9.  
 As shown in Figure 7, after 7 days of treatment 
with simvastatin alone, LDL-C was lowered by ~ 22% 
(-29 mg/dl). In comparison, 7 days post a single IV 3 
mpk dose of 1B20, LDL-C was lowered by ~20% (-23 
mg/dl). Note that results obtained with lean monkeys 
would predict that at 7 days post dosing with 1B20, 
the LDL-C lowering is past its maximal effect, which 
would explain the modest 20% lowering observed at 
this  time  point  in  this  study.  Nevertheless,  in  the 
combination  1B20  +  simvastatin  arm  of  the  study, Int. J. Biol. Sci. 2012, 8 
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LDL-C was lowered by ~ 40% (48 mg/dl), suggestive 
of an additive effect of these agents. 
 To assess target engagement of PCSK9 by 1B20, 
levels of total PCSK9 and free (unbound) PCSK9 were 
measured in this study (Figure 8). At 7 days post 1B20 
dosing alone or  in combination with  simvastatin,  ~ 
10-11  fold  increases  in  total  PCSK9  levels  were  ob-
served for both conditions; however, the levels of free 
PCSK9 remained low which corresponded to calcu-
lated levels of ~ 90% target engagement. In compari-
son,  in  lean  healthy  monkeys,  the  increase  in  total 
PCSK9  levels  with  1B20  treatment  was  relatively 
modest (2-3 fold). Additionally, even at 14 days post 
treatment, despite calculated levels of TE of ~ 50-60%, 
the levels of total PCSK9 in this study were 3.5 fold 
higher  than  untreated  levels,  suggesting  that  accu-
mulation  of  PCSK9  may  contribute  to  the  LDL  re-
bound in 1B20-treated monkeys. In comparison, tran-
sient increases in the levels of total PCSK9 observed in 
both the lean monkey and mouse studies returned to 
untreated levels by 14 days post dosing with 1B20.  
 
 
Figure 7.  Effects of Simvastatin, 1B20 alone and 1B20 + Simvastatin combination on plasma LDL-C in 
metabolic syndrome monkeys (n = 10). A. Study design. Monkeys were treated with vehicle in weeks 1 and 2, 
simvastatin in weeks 3 and 4 (30mg/kg/day in food), followed by vehicle in weeks 5 and 6. At the start of week 7, a single 3 
mpk IV dose of 1B20 was administered to each monkey. Given the result obtained in lean monkeys, it was anticipated that 
LDL-C would return to baseline levels at 14 days post this first dose. At the start of week 9, a second dose of single 3 mpk 
IV 1B20 was administered together with daily dosings of simvastatin in food treats. During the study, weekly plasma samples 
were collected for measurements of LDL-C. B. At day 7 post dosing with simvastatin alone, LDL-C was lowered by ~22%; 
at day 7 post dosing with 1B20 alone, LDL-C was lowered by ~20%; at day 7 post dosing with simvastatin/1B20 combination, 
LDL-C was lowered by ~40%, indicating statin additivity. Int. J. Biol. Sci. 2012, 8 
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Figure 8.  Effects of Simvastatin, 1B20 alone and the combination on levels of plasma total PCSK9, free 
PCSK9 and calculated target engagement in metabolic syndrome monkeys. At 7 days post dosing with 1B20 or 
1B20/simvastatin combination, total PCSK9 levels were increased by ~10 fold, yet free PCSK9 levels remained low, cor-
responding to ~90% target engagement. 
 
 
 
Figure 9.  Free and total PCSK9 (secreted) after 1B20 treatment in human primary hepatocytes. 1B20 
treatment on human primary hepatocytes increased secreted total PCSK9 protein and decreased free (unbound) PCSK9, 
with and without statin treatment. 
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Effects of 1B20 treatment in human primary 
hepatocytes 
In order to assess the mechanism of action of an-
ti-PCSK9 antibodies, a cell-based system was devel-
oped using human primary hepatocytes to model the 
in-vivo  observations.  1B20  treatment  reduced  free 
PCSK9 levels, and increased total (free + bound) se-
creted  PCSK9  levels  in  culture  medium  (Figure  9). 
Interestingly, these effects of 1B20 were observed with 
and  without  simvastatin  treatment.  These  results 
were  consistent  with  the  changes  in  plasma  PCSK9 
levels  observed  in  mouse  and  monkey  studies.  We 
hypothesize that the increases in total PCSK9 might be 
attributed  to  the  tight  binding  of  1B20  to  PCSK9, 
leading  to  the  inhibition  of  cellular  clearance  of 
PCSK9. Indeed, we observed blockade of PCSK9 up-
take by 1B20 in human primary hepatocytes (Figure 
10).  
As  part  of  the  primary  hepatocytes  study,  we 
measured PCSK9 and LDLR mRNA to evaluate the 
possible effect of 1B20 treatment on SREBP tone. As 
shown  in  Figure  11,  simvastatin  treatment  induced 
increases  in  PCSK9  and  LDLR  mRNAs,  and  1B20 
treatment  partially  reversed  this  induction  in  a 
dose-dependent manner. This is consistent with the 
notion that PCSK9 inhibition would lead to increased 
cellular cholesterol uptake and decreased SREBP tone, 
and  also  is  in  agreement  with  reductions  of 
PCSK9/LDLR  mRNA  levels  in  the  livers  of  mice 
treated with 1B20. To further evaluate the transcrip-
tional  effect  of  1B20,  mRNA  levels  of  genes  repre-
senting  major  lipid  metabolism  pathways  were 
measured. As shown in Table 3, comparing 1B20 + 
simvastatin combination versus simvastatin alone, the 
mRNA  levels  of  key  genes  in  both  cholesterol  and 
fatty  acid  synthesis  pathways  were  reduced,  con-
sistent with a reduced SREBP activity. 
 
Table 3. Messenger RNA expression of SREBP-regulated 
key genes in cholesterol and fatty acid synthesis pathways 
was reduced in human primary hepatocytes comparing 
treatment with 1B20 + simvastatin versus simvastatin alone. 
Gene symbol  % Change  P value 
ACSS2  34% down  0.018 
FDPS  37% down  0.002 
IDI1  41% down  0.005 
MVD  40% down  0.002 
HMGCR  22% down  0.049 
CYP51A1  25% down  0.05 
SCD  36% down  0.02 
FADS1  22% down  0.01 
FADS2  32% down  0.007 
PCSK9  20% down  0.04 
LDLR  27% down  0.01 
Genes involved in cholesterol synthesis: ACSS2, FDPS, IDI1, MVD, 
HMGCR, and CYP51A1. Genes involved in fatty acid synthesis: 
ACSS2, SCD, FADS1, and FADS2. 
  
 
 
 
 
 
 
Figure 10. 1B20 blocks PCSK9 uptake in human primary hepatocytes. AF647-labeled PCSK9, alone or pre-mixed 
with antibody, was incubated with human primary hepatocytes for 5 hr. Cells were washed and cellular fluorescent levels 
were quantified on ArrayScan. 1B20 blocks PCSK9 uptake, suggesting that the increases in plasma total PCSK9 might be due 
to decreased cellular clearance of PCSK9 by hepatocytes. 
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Figure 11. PCSK9/LDLR mRNA expression after 1B20 treatment in human primary hepatocytes. 1B20 
treatment significantly reduced PCSK9 and LDLR mRNAs in the presence of simvastatin. 
 
Discussion 
 Although statin therapy has been used success-
fully  in  treating  hypercholesterolemia,  a  significant 
percentage  of  patients  still  do  not  reach  the  target 
LDL-C  levels  and  continue  to  have  cardiovascular 
events. In addition, a segment of the patient popula-
tion is statin intolerant. Therefore there is a significant 
unmet medical need for additional therapies to lower 
LDL-C  and  cardiovascular  risk.  PCSK9  has  been 
proven to be a promising new therapeutic target for 
treating  hypercholesterolemia  and  coronary  heart 
disease by human genetic studies. Here we report an 
anti-PCSK9 monoclonal antibody 1B20, similar to an 
internal antibody 1D05 (23) binds to PCSK9 with high 
affinity,  disrupts  PCSK9–LDLR  protein  interaction, 
and completely blocks PCSK9 inhibition  on cellular 
LDL  uptake.  More  importantly,  1B20  treatment  in-
duced robust 50-70% plasma LDL-C lowering in mice 
in a multiple dosing study, increased hepatic LDLR 
protein,  and  reduced  hepatic  PCSK9  and  LDLR 
mRNAs. In rhesus monkeys, both IV and SC dosing of 
1B20 led to robust and long-lasting LDL-C lowering. 
Furthermore, for the first time, our study in metabolic 
syndrome monkeys demonstrated that the combina-
tion  of  1B20  plus  simvastatin  reduced  LDL-C  more 
than simvastatin or 1B20 alone, highlighting the ad-
vantage of an anti-PCSK9 antibody/statin combina-
tion therapy over either treatment alone. Consistent 
with in vivo observations, 1B20 treatment in human 
primary hepatocytes reduced PCSK9 mRNA on top of 
simvastatin  while  increasing  secreted  total  PCSK9 
protein, indicating that the PCSK9 protein increase is 
due  to  decreased  PCSK9  clearance  rather  than  in-
creased synthesis.    
 For many high risk CHD patients, statin therapy 
alone, even at high doses, does not reduce LDL-C to 
the target goals(1, 2). As shown in Figure 12, statins 
inhibit cellular cholesterol biosynthesis, which leads 
to increased SREBP-2 activity, thus turns on the tran-
scription of both LDLR and PCSK9 genes. Therefore 
statin  treatment  leads  to  both  a  beneficial  effect  of 
increased cellular LDLR protein level, increased LDL 
clearance by liver cells, and a counteractive effect of 
increased PCSK9 protein level. Indeed, increased cir-
culating PCSK9 protein level after statin treatment has 
been reported in both humans and animals (20, 41-44), 
and increased PCSK9 mRNA and protein levels were 
observed in human primary hepatocytes treated with 
simvastatin (Figure 9, 11). The statin-induced increase 
in PCSK9 would attenuate the LDL-lowering efficacy 
of statins since PCSK9 binds to LDLR and triggers its 
trafficking to the lysosome for degradation. The in-
troduction  of  a  PCSK9  inhibitor,  for  example,  an-
ti-PCSK9  antibody  1B20,  would  block 
PCSK9-mediated LDLR protein degradation, increase Int. J. Biol. Sci. 2012, 8 
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hepatic  LDLR  protein  level  and  LDL  clearance, 
therefore is expected to be additive to statins in LDL 
lowering. Indeed, in our study in metabolic syndrome 
monkeys, 1B20 + simvastatin combination treatment 
lowered LDL cholesterol more than 1B20 or simvas-
tatin alone (Figure 7). Although liver samples could 
not be obtained from the monkeys, we did analyze 
mouse livers from 1B20 treatment, and observed an 
increase  in  liver  LDLR  protein  (Figure  1).  Interest-
ingly,  we  observed  reductions  in  liver  LDLR  and 
PCSK9 mRNAs in 1B20-treated mice (Figure 3), con-
firming that the increase in liver LDLR protein was 
not due to increased LDLR mRNA expression, rather 
due  to  decreased  post-transcriptional  LDLR  protein 
degradation. The decreases in liver LDLR and PCSK9 
mRNAs  were  most  likely  attributed  to  a  feedback 
response, as cellular SREBP-2 activity in hepatocytes 
would be reduced due to increased LDLR-mediated 
LDL uptake leading to increased cellular cholesterol 
content following 1B20 treatment, and both LDLR and 
PCSK9 gene transcription are regulated by SREBP-2. 
Both LDLR and PCSK9 mRNAs eventually returned 
to  baseline.  Consistent  with  decreased  LDLR  and 
PCSK9  mRNAs  in  mouse  livers  following  1B20 
treatment, we observed dose-dependent decreases in 
LDLR  and  PCSK9  mRNAs  in  human  primary 
hepatocytes  treated  with  1B20  in  the  presence  of 
simvastatin (Figure 11). In addition, we also observed 
reductions in other SREBP-inducible genes, including 
genes involved in cholesterol and fatty acid synthesis 
(Table 3), suggesting a suppressed SREBP activity.  
 In  mouse  and  monkey  efficacy  studies,  1B20 
treatment led to decreases in plasma free (unbound) 
PCSK9  levels,  and  increases  in  plasma  total  PCSK9 
levels.  We  speculate  this  increase  is  caused  by  the 
sequestering of PCSK9 by 1B20, which blocks PCSK9 
uptake and clearance by the liver, the major organ for 
PCSK9 clearance in the body. Similar to the observa-
tions with 1B20, treatment of monkeys with the 1D05 
antibody (23) resulted in increases, to a lesser extent, 
in plasma total  PCSK9. Consistent with  the in vivo 
results, we observed decreases in free PCSK9 levels 
and  increases  in  total  PCSK9  (secreted)  after  1B20 
treatment  in  human  primary  hepatocytes,  with  and 
without simvastatin. Our finding that 1B20 blocks the 
internalization  of  PCSK9  into  human  primary 
hepatocytes  suggests  that  this  antibody  inhibits 
PCSK9 clearance by hepatocytes, which in turn leads 
to the accumulation of PCSK9 in the circulation. In-
creased  PCSK9  synthesis  is  ruled  out  since  PCSK9 
mRNA levels were reduced in both mouse study and 
human primary hepatocytes. It is important to point 
out the PCSK9 is antibody-bound, therefore function-
ally inactive in promoting LDLR degradation.  
 
 
Figure 12. A PCSK9 inhibitor is expected to be additive to statins in LDL lowering. Statins inhibit cholesterol 
biosynthesis, leading to increased cellular SREBP-2 activity, and increased transcription of SREBP-2-inducible LDLR and 
PCSK9 mRNAs. Therefore statins increase cellular LDLR protein, leading to increased LDL clearance and lower circulating 
LDL. At the same time, statins also increase PCSK9 protein which binds to LDLR and triggers LDLR protein trafficking to the 
lysosome for degradation. Therefore, statin-induced PCSK9 increase limits statin's efficacy of LDL lowering. The intro-
duction of a PCSK9 inhibitor would disrupt the interaction between PCSK9 and LDLR, raise LDLR protein, and be additive 
to statins in LDL lowering. Int. J. Biol. Sci. 2012, 8 
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We acknowledge that as  with all the antibody 
therapies, the cost is an issue. The proposed strategy is 
that  the  mAb  therapy  would  be  primarily  used  in 
high  risk  patients  who  have  had  cardiovascular 
event(s), and those who are statin-intolerant. The ef-
ficacy of 1B20 in LDL lowering is similar to the other 
published  antibodies  (22,  23),  considering  that  they 
were tested in different animal models. In terms of 
other therapeutic approaches, RNAi technology tar-
geting PCSK9 was reported in lowering LDL in ani-
mals (21), but the feasibility of the long term use of 
this new technology in humans is currently unknown. 
EGF-A mimetics are expected to inhibit the interaction 
between PCSK9 and LDLR, but the issue is that they 
tend to have very poor pharmacokinetics (short half 
life) in vivo.  
 In  summary,  the  data  presented  here  suggest 
that  antibodies  targeting  PCSK9  could  provide  pa-
tients  powerful  LDL  lowering  efficacy  on  top  of 
statins and would be expected to lower cardiovascu-
lar risk. Our findings in human primary hepatocytes 
demonstrate the critical role of liver cells and provide 
new insight in PCSK9 biology. The anti-PCSK9 anti-
body 1B20 can serve as a valuable tool in further elu-
cidating the mechanism of action of PCSK9. Finally, 
the results from this study will help in the design of 
next generation PCSK9 inhibitors and clinical trials.  
Materials and Methods 
Isolation of anti-PCSK9 antibody 1B20 
The  human  combinatorial  antibody  HuCAL 
GOLD phage display libraries were panned against 
recombinant human PCSK9-V5-His protein immobi-
lized on Nunc Maxisorp plates. Initial expression and 
purification of 1B20 Fab was performed as previously 
described(28). Full 1B20 IgG2m4 was expressed and 
purified from CHO cells. 
Antibody inhibition of PCSK9 – LDLR interac-
tion 
Surface plasmon resonance (SPR) measurements 
were carried out with a Biacore instrument (Biacore 
S51, Uppsala, Sweden) at 25oC. Human recombinant 
LDLR  (R&D,  Cat  #  2148-LD/CF  @  40  ug/ml)  was 
immobilized in 10 mM Na-acetate pH 4.5 on a CM5 
sensor  chip  (GE,  BR-1005-31)  using  standard  EDC 
[1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide-H
Cl]  and  NHS  (N-hydroxysuccinimide)  coupling 
chemistry  and  subsequent  blocking  with  ethanola-
mine  per  manufacturer's  instructions.  The  targeted 
immobilization level was 1000 resonance units (RU). 
Running  buffer  was  standard  HBS-N  buffer  (GE, 
BR-1006-70) supplemented with 1 mM calcium chlo-
ride (Fluka, # 21114) and 0.005% surfactant P20 (GE, 
BR-1000-54). Human, rhesus, rat and mouse PCSK9 
were diluted in running buffer to a concentration of 
around  25  nM  and  varying  amounts  of  1B20  were 
added. For analysis typically a sample volume of 120 
ul was injected at a flow rate of 30 ul/min. Regenera-
tion of the CM5 chip was accomplished with a short 
burst of 3 ul of 0.01 N HCL. Data were analyzed using 
BIAevaluation software.  
AF546-labeled LDL Uptake Assay 
HepG2  cells  were  plated  in  a  96-well 
poly-D-lysine-coated plate (Corning) at a density of 
30,000 cells/well in DMEM containing 10% FBS. After 
24 hr, the medium was switched to DMEM lacking 
serum.  After  18  hr,  the  medium  was  removed  and 
purified PCSK9 protein was added to the cells in 100 
µl  of  mixture  A  (DMEM  containing  10%  lipopro-
tein-deficient Serum, 10 mg/ml AF-labeled LDL and 
2ug/ml PCSK9). 1B20 antibody was titrated in pres-
ence of 2ug/ml PCSK9, starting with 100ug/ml. An-
tibody-PCSK9  mixture  was  incubated  at  room  tem-
perature for 20 minutes before added to the cells. The 
plates were incubated at 37 °C for 5 hr, and the cells 
were  washed  quickly  with  Tris-buffered  saline 
(Bio-Rad)  containing  2  mg/ml  BSA.  The  wash  step 
was repeated, but this time the wash buffer was in-
cubated for 2 min with the cells. Finally, the cells were 
quickly  washed  twice  with  Tris-buffered  saline 
(without BSA) and lysed in 100µl of RIPA buffer. The 
lysate was transferred to a 96-well black plate (Ther-
mo  LabSystems),  and  fluorescence  was  measured 
using  a  Spectra-MAX  tunable  spectrofluorometer 
(Molecular  Devices)  at  an  excitation  wavelength  of 
520nm and an emission wavelength of 580 nm. Total 
cellular protein was measured in each well using the 
BCA protein assay, and the fluorescence units were 
normalized to total protein. The amount of 1B20 re-
quired for 50% inhibition  of PCSK9 function (IC50) 
was  determined  by  fitting  data  to  a  sigmoidal 
dose-response  curve  using  nonlinear  regression 
(GraphPad Software Inc.). 
1B20 treatment in CETPtg[LDLR+/-] mice 
All animal studies were approved by the Insti-
tutional Animal Care and Use Committee (IACUC) at 
Merck  Research  Laboratories.  A  transgenic  mouse 
model expressing the human CETP transgene and a 
single  allele  copy  of  the  LDL-receptor 
(CETPtg[LDLR+/-])  was  utilized.  12-week  old  male 
mice were treated IV with indicated doses of 1B20 and 
serum samples were collected at indicated time points 
for  measurements  of  LDL-C,  total  and  free  PCSK9, 
and  1B20  levels.  Serum  samples  were  treated  with Int. J. Biol. Sci. 2012, 8 
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lipase  inhibitors  and  protease  inhibitors  (Sigma), 
stored at 4°C and assayed within 7 days of sample 
collection.  LDL-C  was  measured  with  LDL  Direct 
Select Cholesterol Reagent (Equal Diagnostics). Liver 
samples  were  flash  frozen  in  liquid  nitrogen  and 
stored at -80oC until analysis.  
Mouse liver LDLR western blot 
100mg of mouse liver was homogenized in 500ul 
RIPA Lysis buffer with 1x PMSF, sodium orthovana-
date and protease inhibitors (Santa Cruz, sc-24948) on 
ice,  centrifuged  at  10,000g  for  30  minutes.  50ug  of 
protein was loaded to Novex Tris-Glycine gel (4-12%, 
Invitrogen),  transferred  to  nitrocellulose  membrane. 
The  membrane  was  blocked  with  blocking  buffer  ( 
1xTBS (Fisher ), 1% tween-20 and 5% non fat mik) at 
RT  for  an  hour,  washed  3x  with  wash  buffer 
(1xTBS,1% tween-20), then incubated with LDLR an-
tibody (R&D Systems, anti-mLDLR goat IgG ,Cat # 
AF2255,  1:1000  diluted  in  blocking  buffer)  and  an-
ti-tubulin (Sigma,T5168) at 4 0C overnight. After wash, 
the  membrane  was  blot  with  HRP-anti-goat  (GE 
Healthcare)  and  HRP-anti-mouse  antibodies  (GE 
Healthcare) for 45min, then washed 3 times. ELC plus 
(GE  Healthcare,  RPN2132)  treated  membrane  was 
scanned on Typhoon 9400(GE Healthcare).  
1B20 treatment in healthy rhesus monkeys  
To  characterize  pharmacokinetics  (PK),  phar-
macodynamics  (PD)  and  target  engagement  (TE)  of 
1B20, single dose IV and SC studies were conducted 
in 15-year old male rhesus monkeys (Macaca mulatta). 
All rhesus monkeys used in the study were naïve to 
biologics.  All  studies  were  approved  by  the  Merck 
Research Laboratories Institutional Animal Care and 
Use Committee (IACUC). 
Each  animal  (n=6/group)  received  a  single  in-
travenous injection of 1B20 at 1 or 10 mg/kg via the 
cephalic vein. For SC administration, rhesus monkeys 
(n=3/group) were given a 1 or 10 mg/kg subcutane-
ous dose of 1B20 between the shoulder blades. In all 
studies,  blood  samples  were  collected  from  the  sa-
phenous/femoral  vessel  at  designated  time  points 
post  dosing  and  the  resulting  plasma/serum  was 
used for PK (1B20 levels), PD (LDL-C level) and target 
engagement (free and total PCSK9) measurements. 
A 1B20 specific, enzyme-linked immunosorbent 
assay  (ELISA)  was  used  to  quantify  1B20.  Briefly, 
ELISA plates are coated with an anti-PCSK9 capture 
antibody,  which  does  not  compete  with  1B20  for 
binding to PCSK9, followed by recombinant PCSK9 
immobilization. Serum samples containing 1B20 are 
applied to the plates pre-coated with the anti-PCSK9 
antibody and PCSK9. Bound 1B20 is detected with an 
anti-human IgG2(Fc)-specific detection antibody.  
Pharmacokinetic  parameters  were  estimated 
using a non-compartmental method with WinNonlin 
5.01 (Pharsight Inc). Clearance (CL) was calculated as 
the dose divided by the area under the serum con-
centration-time curve from zero to infinity (AUC0-). 
The  apparent  terminal  half-life  (t1/2)  was  estimated 
from the slope of the terminal phase of the log serum 
concentration-time data. The volume of distribution at 
steady  state  (Vdss)  was  determined  using 
non-compartmental  method:  Vdss  =  (Dose  iv  x 
AUMC0-)/  (AUC0-)2,  where  AUMC0-  is  the  total 
area under the first moment of the drug concentra-
tion-time curve from time zero to infinity.  
Rhesus target engagement Delfia assay:  
96-well  Immulon  4HBX  plates  (Thermo  Lab 
systems part # 3855) were coated with 5ug/ml of an-
ti-PCSK9  antibody  E07  at  4C  overnight,  washed  3 
times with 300ul wash buffer (1x TBST buffer, Sigma, 
T9039) and then blocked 1h at RT with blocking buffer 
(  1X  TBS  (Fisher  Scientific,BP2472),  1%  BSA,  0.05% 
Tween-20).  Rhesus  plasma  (1:4  or  1:8)  and  rhesus 
PCSK9  standards  were  diluted  in  assay  buffer  (1% 
BSA in PBS). After 3 x wash with wash buffer, 50ul of 
diluted  plasma  samples  or  PCSK9  standards  were 
added on the plate and incubated at 37 C for 1h, fol-
lowed by 3x 300ul wash. 50ul of either biotinylated 
1H23 (detects total PCSK9) or biotinylated 1B20 (de-
tects  free  PCSK9)  at  1ug/ml  in  Defila  assay  buffer 
(Perkin Elmer, 1244-111) were added to the plate and 
incubated  at  RT  for  1h.  After  3x  wash  with  wash 
buffer, 50ul of 1:1000 Streptavidin/Europium (Perkin 
Elmer, 1244-360) in Defila assay buffer was added on 
the plate, incubated for 20min at RT, followed by 3x 
wash  and  100ul  of  DELFIA  Enhance  (Perkin  Elmer 
part # 1244-105). Plate was kept at RT, protected from 
light for 1h and read on Europium reader (Envision 
2103). The bound PCSK9 is calculated as the differ-
ence between total and free PCSK9. The percentage of 
target  engagement  is  defined  as  the  percentage  of 
bound PCSK9 in total PCSK9. 
1B20 treatment in metabolic syndrome 
monkeys with and without a statin 
To assess the statin additivity effects of 1B20, a 
study was designed in collaboration with B. C. Han-
sen in a cohort of metabolic syndrome monkeys. This 
multiple arm study was designed to compare the ef-
fects of simvastatin, 1B20, and simvastatin plus 1B20 
in the same cohort of 10 monkeys. Simvastatin was 
given at a 30 mg/kg/day dose in food treats and 1B20 
was administered IV as a 3 mpk dose. The study de-Int. J. Biol. Sci. 2012, 8 
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sign  is  as  follows:  19-year  old  male  monkeys  were 
treated with vehicle in weeks 1 and 2, simvastatin in 
weeks 3 and 4 (30mg/kg/day in food), followed by 
vehicle in weeks 5 and 6. At the start of week 7, a sin-
gle 3 mpk IV dose of 1B20 was administered to each 
monkey. Given the result obtained in lean monkeys, it 
was anticipated that LDL-C would return to baseline 
levels at 14 days post this first dose. At the start of 
week 9, a second dose of single 3 mpk IV 1B20 was 
administered together with daily dosings of simvas-
tatin in food treats. During the study, weekly plasma 
samples were collected for measurements of LDL-C., 
total and free PCSK9.  
Lipoprotein analysis (RoboFplcLipidANalysis) 
To  generate  lipoprotein  profiles,  plasma  was 
fractionated by chromatography over Superose-6 size 
exclusion column (GE LifeSciences, Inc.) on an Ulti-
mate 3000 Series HPLC system (Dionex Corporation). 
Total cholesterol levels in the column effluent were 
continuously  measured  via  in-line  mixture  with  a 
commercially  available  enzymatic  colorimetric  cho-
lesterol  detection  reagent  (Total  Cholesterol  E,  cat 
#439-17501;  Wako  USA)  followed  by  downstream 
spectrophotometric detection of the reaction products 
at  600nm  absorbance.  The  first  peak  of  cholesterol 
eluted from the column was attributed to VLDL, the 
second peak to LDL and the third to HDL; the area 
under each peak was calculated using software pro-
vided with the HPLC. The cholesterol concentrations 
for each lipoprotein fraction  were calculated by ex-
trapolating the ratio of the corresponding peak areas 
to total peak areas and multiplying by the total cho-
lesterol concentration measured in the samples. Total 
cholesterol was measured in a microtiter plate from a 
1:1  mix  of  100ul  Cholesterol  E  reagent  and  2.5ul 
plasma diluted in PBS to 100ul, incubated at 37oC for 
30 minutes and then read at 600nm in a SpectraMAX 
plate reader (Molecular Devices). Cholesterol stand-
ards were provided in the kit as a 200mg/dl Choles-
terol stock and serially diluted to provide a standard 
curve. Non-HDL measures were calculated using the 
precipitation method detailed in the Wako HDL- E kit 
(cat# 431-52501).  
Human primary hepatocytes model system 
Cryopreserved  plateable  human  primary 
hepatocytes  were  purchased  from  CellzDirect 
(Durham,  NC)  (cat#HMCPIS),  and  cultured  by  fol-
lowing supplier's instructions. On day 1, cells were 
thawed, recovered in cryopreserved hepatocytes re-
covery medium (CHRM, cat#CM7000) and plated in 
Plating  medium  (Williams  E  medium  plus  se-
rum-containing  thawing/plating  supplement, 
cat#CM3000)  at  50,000  cells/well/200ul  on  colla-
gen-coated  96-well  plates  (Becton  Dickinson, 
cat#356649), cultured in 37oC/5%CO2 incubator. On 
day  2,  plating  medium  was  removed  and  replaced 
with Maintenance medium (Williams E medium plus 
maintenance  supplement,  CellzDirect  cat#CM4000). 
This  medium  was  then  replaced  with  Maintenance 
medium  containing  various  concentrations  of  1B20 
antibody  (starting  at  300ug/ml)  with  or  without 
simvastatin. On day 6, culture medium was harvested 
and the secreted free and total PCSK9 protein were 
measured  using  the  same  Delfia  ELISA  method  as 
that used in rhesus monkey target engagement assay. 
mRNA  was  isolated  from  the  cells  using  mRNA 
Catcher Plus kit (Invitrogen, cat#K1570-03) or Qiagen 
Rneasy mini kit, converted to cDNA, and mRNA lev-
els  of  specific  genes  were  measured  using  taqman 
quantitative  PCR,  with  reagents  from  Applied  Bio-
systems. A custom designed PCR array for genes in 
key  lipid  metabolism  pathways  was  developed  in 
collaboration with SABiosciences-Qiagen. 
PCSK9 uptake in human primary hepatocytes.  
On day 1, cryopreserved  plateable human pri-
mary hepatocytes were thawed and plated in Plating 
medium (above) at 40,000 cells/well/100ul on colla-
gen-coated  96-well  plates  (Nunc,  cat#152036),  and 
cultured  in  37oC/5%CO2  incubator.  Six  hours  after 
plating,  medium  was  removed,  wells  washed  with 
PBS, replaced with cold Maintenance medium (above) 
containing  0.25  mg/ml  Geltrex  (Invitrogen, 
cat#12760-021), and  returned  to  the  37oC  incubator. 
On day 2 and 3, medium was removed and replaced 
with warm Maintenance medium. On day 4, medium 
was  removed  and  replaced  with  Maintenance  me-
dium  containing  15  ug/ml  AF647-labeled  human 
PCSK9 alone (protect from light) or with titrations of 
1B20 starting at 300 ug/ml. AF647-PCSK9 and 1B20 
were pre-mixed for 20 min at room temperature. Cells 
were  incubated  at  37oC/5%CO2  for  5  hours.  Cells 
were washed with TBS containing 2 mg/ml BSA, then 
TBS. To exclude dead cells, cells  were stained  with 
LIVE/DEAD fixable Dead Cell green dye (Invitrogen, 
cat#L23101) for 20 min at room temperature by fol-
lowing manufacturer's instructions, and washed with 
TBS. Cell nuclei were stained and cells were fixed in 
TBS  containing  1  ug/ml  Hoechst's  33342  dye  (Invi-
trogen,  cat#H3570)  and  4%  paraformaldehyde  (Pol-
ysciences, cat#18814) for 20 min at room temperature. 
Plates were washed twice in TBS, sealed and stored 
overnight at 4oC. On day 5, cells were analyzed and 
cellular content of AF647-PCSK9 were measured on 
ArrayScan.  Int. J. Biol. Sci. 2012, 8 
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Statistics  
Student’s t-tests (two-tailed and unpaired) were 
performed  and  P<0.05  was  considered  statistically 
significant. The error bars are SEMs. 
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